title: Treatment of collecting duct carcinoma: current status and future perspectives.
abstract: BACKGROUND
  Chemotherapy for collecting duct carcinoma (CDC) has demonstrated only limited efficacy in the advanced setting. The present study evaluated the activity of targeted therapies in metastatic CDC.
  
  
  METHODS
  We evaluated a cohort of 384 consecutive patients with metastatic renal cell carcinoma (mRCC). The characteristics of patients with CDC were compared against those of the remaining cohort. All patients with CDC were treated with targeted therapies.
  
  
  RESULTS
  Thirteen patients with advanced CDC were referred to our Center (incidence: 3.4% of all mRCC). Median age was 57 and 62 years in the CDC and non-CDC groups, respectively. The overall disease control in the CDC population was 23%, and median overall survival was 4 (95% confidence interval(CI)=2.4-5.6) months. Three patients obtained a satisfying response (disease control lasting 6-33 months).
  
  
  CONCLUSIONS
  CDC has a poor prognosis compared to non-CDC renal cell carcinoma. Treatment for CDC represents a future challenge and targeted therapies may play a role in selected cases.
authors: Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy. giuseppe.procopio@istitutotumori.mi.it.
authors: Giuseppe
authors: G
authors: Procopio
authors: Isabella
authors: I
authors: Testa
authors: Roberto
authors: R
authors: Iacovelli
authors: Paolo
authors: P
authors: Grassi
authors: Elena
authors: E
authors: Verzoni
authors: Enrico
authors: E
authors: Garanzini
authors: Maurizio
authors: M
authors: Colecchia
authors: Tullio
authors: T
authors: Torelli
authors: Filippo
authors: F
authors: De Braud
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000098:blood supply* / Q000188:drug therapy*; D015331:Cohort Studies; D006801:Humans; D007191:Indazoles; D007680:Kidney Neoplasms / Q000098:blood supply* / Q000188:drug therapy*; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007191:Indazoles; D010671:Phenylurea Compounds; D011743:Pyrimidines; D013449:Sulfonamides; D009536:Niacinamide; C401859:temsirolimus; C516667:pazopanib; D000077157:Sorafenib; D020123:Sirolimus
keywords: Bellini disease; collecting ducts carcinoma; renal carcinoma; targeted therapy